The Rotterdam Eye Hospital
- Address
- lock Available on a paid plan
Eye Diseases
The Rotterdam Eye Hospital is active in ophthalmology research focused on a range of vision-threatening conditions. Current studies examine exudative age-related macular degeneration, neovascular age-related macular degeneration, geographic atrophy, central serous chorioretinopathy, and persistent corneal epithelial defect, with the goal of improving treatment effectiveness and patient outcomes.
- Research includes testing new approaches for retinal disease, evaluating treatment combinations, and assessing therapies that may better preserve vision.
- Studies also look at healing support for corneal surface disease and symptom control in chronic eye conditions.
- The site supports clinical research aimed at both short-term improvement and longer-term disease management.
These trials reflect a strong focus on retina, macular, and corneal disorders, with an emphasis on finding safer and more effective care options.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Research at this site also covers inherited eye disease, especially conditions that affect vision from an early age or progress over time. Key studies involve retinitis pigmentosa and Stargardt disease, focusing on whether emerging therapies can slow disease progression and support retinal function.
- Investigations are centered on inherited retinal disorders linked to genetic causes and long-term vision loss.
- The research aims to evaluate whether new treatments can improve disease control and protect remaining sight.
- These studies add an important genetic ophthalmology dimension to the hospital’s trial portfolio.
The work at Rotterdams Oogheelkundig Instituut highlights efforts to advance care for patients with rare, hereditary conditions where treatment options remain limited.
Specialized Vision and Ocular Surface Research
Several trials at the Rotterdam Eye Hospital focus on specific eye conditions such as acquired blepharoptosis and persistent corneal epithelial defect. These studies are designed to test new therapies that may improve eyelid function or support corneal healing more effectively than current care.
- Research in this area includes evaluating treatments for drooping eyelids that can affect vision and daily comfort.
- Ocular surface studies are examining ways to promote complete healing in hard-to-treat corneal defects.
- The site’s work combines symptom relief, visual function, and tissue repair as key research goals.
Together, these studies show a broad commitment to improving both common and rare eye disorders through clinical investigation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Janssen Cilag International1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in The Rotterdam Eye Hospital
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Janssen Cilag International | Phase II | Not Recruiting | Aug 2023 | Feb 2026 |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adeno-Associated Virus Serotype 2 Encoding Soluble Cd59 | 2 | Unknown | 2023-08-11 | 2025-02-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
